<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS109280</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.25.424300</article-id>
<article-id pub-id-type="archive">PPR258071</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Disruption of nasal bacteria enhances protective immune responses to influenza A virus and SARS-CoV-2 infection in mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nagai</surname>
<given-names>Minami</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moriyama</surname>
<given-names>Miyu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ichinohe</surname>
<given-names>Takeshi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Division of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan</aff>
<author-notes>
<fn id="FN1">
<label>2</label>
<p id="P1">Lead Contact</p>
</fn>
<corresp id="CR1">
<label>*</label>Correspondence: <email>ichinohe@ims.u-tokyo.ac.jp</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>27</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P2">Gut microbiota plays a critical role in the induction of adaptive immune responses to influenza virus infection. However, the role of nasal bacteria in the induction of the virus-specific adaptive immunity is less clear. Here we demonstrate that while intranasal administration of influenza virus hemagglutinin vaccine alone was insufficient to induce the vaccine-specific antibody responses, disruption of nasal bacteria by lysozyme or addition of culturable oral bacteria from a healthy human volunteer rescued inability of the nasal bacteria to generate antibody responses to intranasally administered the split-virus vaccine. Myd88-depdnent signaling in the hematopoietic compartment was required for adjuvant activity of intranasally administered oral bacteria. In addition, we found that the oral bacteria-combined intranasal vaccine induced protective antibody response to influenza virus and SARS-CoV-2 infection. Our findings here have identified a previously unappreciated role for nasal bacteria in the induction of the virus-specific adaptive immune responses.</p>
</abstract>
<kwd-group>
<kwd>mucosal immunity</kwd>
<kwd>intranasal vaccine</kwd>
<kwd>adjuvant</kwd>
<kwd>SARS-CoV-2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P3">Respiratory infectious diseases such as influenza and coronavirus disease 2019 (COVID-19) cause substantial morbidity and mortality. Influenza A virus is responsible for annual epidemics that cause severe morbidity and mortality involving 3 to 5 million people worldwide. In addition, the constant pandemic potential of newly emerging viruses remains a serious threat to public health, the economy and society as illustrated by the recent COVID-19 global pandemic. Therefore, there is an urgent need to develop effective vaccines against not only seasonal influenza viruses but also against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</p>
<p id="P4">Since it is difficult to predict which strain of influenza virus or coronavirus cause a pandemic, it is advantageous to produce vaccines that induce cross-protective immunity against variants of the particular virus strain. Mucosal immunity induced by natural infection of influenza virus is more effective and cross-protective against heterologous virus infection than systemic immunity induced by parenteral vaccines (<xref ref-type="bibr" rid="R37">S. Tamura &amp; Kurata, 2004</xref>). It is believed that the virus-specific IgA in upper respiratory tract is more cross-protective against heterologous influenza viruses compared with the virus-specific IgG in the serum due to its dimeric or tetrameric forms (higher avidity) and location (<xref ref-type="bibr" rid="R18">Liew, Russell, Appleyard, Brand, &amp; Beale, 1984;</xref> <xref ref-type="bibr" rid="R36">Suzuki et al., 2015</xref>). Indeed,polymeric immunoglobulin receptor-knockout mice failed to secrete nasal IgA and protect against heterologous virus challenge (<xref ref-type="bibr" rid="R3">Asahi et al., 2002</xref>). Therefore, induction of the virus-specific secretory IgA in the upper respiratory tract by intranasal vaccination has a great advantage in conferring protection against an unpredictable pandemic of viral pathogens such as the swine-origin H1N1 and avian-origin H7N9 influenza A viruses, or zoonotic origin of SARS-CoV-2 (<xref ref-type="bibr" rid="R8">Gao et al., 2013;</xref> <xref ref-type="bibr" rid="R26">Neumann, Noda, &amp; Kawaoka, 2009</xref>). In the effort to develop effective intranasal vaccines, several adjuvants such as cholera toxin (<xref ref-type="bibr" rid="R41">Watanabe et al., 2002</xref>), synthetic double-stranded RNA poly(I:C) (<xref ref-type="bibr" rid="R11">Ichinohe et al., 2005</xref>), synthetic toll-like receptor 4 agonist (<xref ref-type="bibr" rid="R33">Spinner et al., 2015</xref>), zymosan (<xref ref-type="bibr" rid="R2">Ainai et al., 2010</xref>), flagellin (<xref ref-type="bibr" rid="R32">Skountzou et al., 2010</xref>), immune stimulating complexes (ISCOMs) (<xref ref-type="bibr" rid="R31">Sjolander et al., 2001</xref>), or type-I interferons (<xref ref-type="bibr" rid="R5">Bracci et al., 2005</xref>) have been developed to enhance the vaccine-specific nasal IgA response. While upper respiratory tract contains commensal bacteria (<xref ref-type="bibr" rid="R4">Bassis et al., 2015;</xref> <xref ref-type="bibr" rid="R7">Clark, 2020</xref>), intranasal administration of split vaccine alone was insufficient to induce the vaccine-specific nasal IgA response (<xref ref-type="bibr" rid="R11">Ichinohe et al., 2005;</xref> <xref ref-type="bibr" rid="R14">Jangra et al., 2020</xref>), suggesting that the amounts of commensal bacteria in upper respiratory tract are insufficient to stimulate the vaccine-specific nasal IgA response.</p>
<p id="P5">A recent study has demonstrated that nasal mucosa-derived <italic>Staphylococcus epidermidis</italic>, one of the most abundant colonizers of healthy human skin and mucosal surface, suppressed influenza virus replication by stimulating IFN-Î» production (<xref ref-type="bibr" rid="R17">Kim et al., 2019</xref>). In addition, influenza virus-infected mice lacking both toll-like receptor 7 (TLR7) and mitochondrial antiviral signaling (MAVS) had elevated nasal bacterial burdens, which resulted in death from pneumonia caused by secondary bacterial infections (<xref ref-type="bibr" rid="R29">Pillai et al., 2016</xref>). In contrast to the role of nasal bacteria in innate antiviral resistance to influenza virus infection or severity of the disease (<xref ref-type="bibr" rid="R17">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="R29">Pillai et al., 2016</xref>), it remains unclear whether nasal bacteria critically regulates the generation of influenza virus-specific adaptive immune responses after infection or intranasal vaccination. Here, we show that depletion of nasal bacteria by intranasal administration of antibiotics enhanced the virus-specific nasal IgA and serum IgG response following influenza virus infection. In addition, we found that lysozyme-induced disruption of nasal bacteria or culturable oral bacteria from a healthy volunteer significantly enhanced the vaccine-specific nasal IgA and serum IgG responses. Myd88-depdnent signaling in the hematopoietic compartment was required for adjuvant activity of intranasally administered oral bacteria. Our findings here have identified a previously unappreciated role for nasal bacteria in the induction of the virus-specific adaptive immune responses.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>Depletion of nasal bacteria enhanced antibodies response to influenza virus infection</title>
<p id="P6">Gut commensal microbiota play a key role in innate and adaptive immune defense against influenza virus infection (<xref ref-type="bibr" rid="R1">Abt et al., 2012</xref>; <xref ref-type="bibr" rid="R6">Bradley et al., 2019</xref>; <xref ref-type="bibr" rid="R10">Ichinohe et al., 2011</xref>; <xref ref-type="bibr" rid="R30">Rosshart et al., 2017</xref>; <xref ref-type="bibr" rid="R34">Steed et al., 2017</xref>; <xref ref-type="bibr" rid="R35">Stefan, Kim, Iwasaki, &amp; Kasper, 2020</xref>). However, the role of oral or nasal bacteria in the induction of mucosal immune responses following influenza virus infection remains unknown. To assess the effects of oral or nasal bacteria in the induction of mucosal immune responses to influenza virus infection, we treated mice intranasally with an antibiotic cocktail for five consecutive days before influenza virus infection. This treatment resulted in significant reduction in the numbers of culturable oral and nasal bacteria (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>).</p>
<p id="P7">Antibiotic-treated mice were then infected intranasally with a mouse-adapted influenza A virus strain A/Puerto Rico/8/1934 (PR8). Surprisingly, influenza virus-specific nasal IgA and serum IgG levels were significantly elevated in the antibiotic-treated group (<xref ref-type="fig" rid="F1">Fig. 1</xref>). This led us to consider the possibility that depletion of commensal bacteria in upper respiratory tract enhances influenza virus replication, resulting in enhancement of the virus-specific antibody responses. However, depletion of commensal bacteria in upper respiratory tract significantly reduced influenza virus replication at 2 days post infection (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2A</xref>). This is consistent with a previous report showing that antibiotic treatment significantly reduce influenza virus replication at early time point (<xref ref-type="bibr" rid="R9">Gopinath et al., 2018</xref>). In addition, the viral replication in upper respiratory tract became comparable between antibiotics-treated and control groups at 3 and 5 days post infection (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2B, C</xref>). These data indicated that the levels of influenza virus replication in upper respiratory tract is unlikely to account for increased the virus-specific antibody responses in antibiotic-treated animals.</p>
</sec>
<sec id="S4">
<title>Lysozyme-induced disruption of nasal bacteria enhances antibody responses induced by intranasal vaccination</title>
<p id="P8">Thus, we next examined the possibility that antibiotic-induced disruption of nasal bacteria releases pathogen-associated molecular patterns, which may act as adjuvants to enhance the virus-specific antibody responses. To assess the possibility that disruption of nasal bacteria acts as adjuvant for intranasal influenza vaccine, we immunized mice intranasally with influenza virus hemagglutinin (HA) protein and lysozyme to disrupt nasal bacteria. We used poly(I:C) adjuvant as a positive control (<xref ref-type="bibr" rid="R11">Ichinohe et al., 2005</xref>). Strikingly, we found that intranasal immunization with HA and lysozyme significantly enhanced the HA-specific nasal IgA and serum IgG responses (<xref ref-type="fig" rid="F2">Fig. 2</xref>). While upper respiratory tract contains commensal bacteria (<xref ref-type="bibr" rid="R4">Bassis et al., 2015</xref>; <xref ref-type="bibr" rid="R7">Clark, 2020</xref>), intranasal administration of hemagglutinin (HA) vaccine alone was insufficient to induce the HA-specific antibody responses (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Taken together, these results suggest that disruption of nasal bacteria by intranasal administration of antibiotics or lysozyme acts as adjuvant for intranasal influenza vaccine.</p>
</sec>
<sec id="S5">
<title>Oral bacteria act as adjuvant for intranasal vaccine</title>
<p id="P9">While upper respiratory tract contains commensal bacteria (<xref ref-type="bibr" rid="R4">Bassis et al., 2015</xref>; <xref ref-type="bibr" rid="R7">Clark, 2020</xref>), we found that relative amounts of 16S rRNA and culturable bacteria in nasal mucosal surface were significantly lower than that in the oral cavity (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). Thus, we next examine whether oral bacteria act as adjuvant for intranasal vaccine. Intranasal vaccination with HA and culturable oral bacteria from mice or a healthy volunteer significantly enhanced the HA-specific nasal IgA and serum IgG responses (<xref ref-type="fig" rid="F3">Fig. 3A, B</xref>). In addition, the oral bacteria from a healthy volunteer stimulated the HA-specific nasal IgA and serum IgG responses in a dose-dependent manner (<xref ref-type="fig" rid="F3">Fig. 3C, D</xref>). Next, we compared the ability of isolated bacterial strains from oral wash sample of a healthy volunteer to stimulate the HA-specific antibody responses. To this end, we immunized mice intranasally with HA and <italic>streptococcus salivarius</italic> (<italic>S. salivarius</italic>), <italic>streptococcus parasanguinis</italic> (<italic>S. parasanguinis</italic>), or <italic>streptococcus infantis</italic> (<italic>S. infantis</italic>). Mice immunized with HA and each isolated bacterial strain induced comparable levels of the HA-specific nasal IgA and serum IgG responses (<xref ref-type="fig" rid="F4">Fig. 4</xref>), suggesting that adjuvant activity of the oral bacteria is unlikely to account for strain specific.</p>
</sec>
<sec id="S6">
<title>Myd88-depdnent signaling in the hematopoietic compartment is required for adjuvant activity of intranasally administered oral bacteria</title>
<p id="P10">Next, we wished to determine the innate immune signaling through pattern-recognition receptors required for adjuvant activity of the oral bacteria. To this end, we immunized WT and MyD88-deficient mice intranasally with HA and culturable oral bacteria from a healthy volunteer and measured the HA-specific nasal IgA and serum IgG responses. The HA-specific nasal IgA and serum IgG responses were found to be completely dependent on MyD88 (<xref ref-type="fig" rid="F5">Fig. 5A, B</xref>). In addition, lysozyme-induced disruption of nasal bacteria stimulated the HA-specific nasal IgA and serum IgG responses in a MyD88-dependent manner (<xref ref-type="fig" rid="F5">Fig. 5C, D</xref>). To determine the cellular compartment responsible for adjuvant activity of oral bacteria, we generated bone marrow (BM) chimeric mice in which only the hematopoietic (WTâMyD88<sup>â/â</sup>) or the stromal cells (MyD88<sup>â/â</sup>âWT) expressed MyD88. After intranasal vaccination with HA and oral bacteria, the HA-specific nasal IgA and serum IgG responses were significantly reduced in MyD88<sup>â/â</sup>âWT BM chimeric mice compared to WTâMyD88<sup>â/â</sup> BM chimeric mice (<xref ref-type="fig" rid="F6">Fig. 6</xref>). These data indicate that MyD88-dependent signaling in the hematopoietic, but not stromal, compartment is required for adjuvant activity of intranasally administered oral bacteria.</p>
</sec>
<sec id="S7">
<title>Oral bacteria-combined intranasal vaccine protects from influenza virus and SARS-CoV-2 infection</title>
<p id="P11">Finally, we examined protective effects of intranasal vaccination with oral bacteria-adjuvanted vaccine against influenza virus and SARS-CoV-2 infection. To this end, we immunized mice intranasally with quadrivalent influenza HA vaccine containing A/California/7/2009 HA together with culturable oral bacteria or lysozyme. Two weeks after the second vaccination, we challenged vaccinated mice intranasally with a heterologous A/Narita/1/2009 (pdm09) strain (<xref ref-type="fig" rid="F7">Fig. 7</xref>). Mice immunized with HA vaccine adjuvanted with oral bacteria or lysozyme significantly reduced the virus titer compared to control mice immunized with the HA vaccine alone (<xref ref-type="fig" rid="F7">Fig. 7</xref>). We next assessed protective effects of intranasal vaccination with oral bacteria-adjuvanted SARS-CoV-2 spike protein against SARS-CoV-2 infection in Syrian hamsters. To this end, we immunized hamsters intranasally with a recombinant SARS-CoV-2 spike protein and culturable oral bacteria from a healthy volunteer. We immunized hamsters subcutaneously with the spike protein alone as a control. We Both the spike- and the virus-specific serum IgG levels were significantly elevated in immunized hamsters (<xref ref-type="fig" rid="F8">Fig. 8A, B</xref>). In addition, immunized hamsters significantly reduced the virus titer compared to naÃ¯ve animals following high-dose (2Ã10<sup>6</sup> pfu of SARS-CoV-2) challenge (<xref ref-type="fig" rid="F8">Fig. 8C</xref>). These data collectively indicated that disruption of nasal bacteria or intranasal administration of oral bacteria compensate inability of nasal bacteria to generate protective adaptive immunity to intranasally administered split vaccines.</p>
</sec>
</sec>
<sec id="S8" sec-type="discussion">
<title>Discussion</title>
<p id="P12">The innate immune system, the first line of defense against pathogens, utilizes pattern recognition receptors (PRRs) to detect pathogen-associated molecular patterns (PAMPs). The recognition of influenza virus by PRRs plays a key role not only in limiting virus replication at early stages of infection, but also in initiating the virus-specific adaptive immune responses. In addition, previous studies have demonstrated that gut commensal microbiota play a key role in innate and adaptive immune defense against influenza virus infection (<xref ref-type="bibr" rid="R1">Abt et al., 2012</xref>; <xref ref-type="bibr" rid="R6">Bradley et al., 2019</xref>; <xref ref-type="bibr" rid="R10">Ichinohe et al., 2011</xref>; <xref ref-type="bibr" rid="R30">Rosshart et al., 2017</xref>; <xref ref-type="bibr" rid="R34">Steed et al., 2017</xref>; <xref ref-type="bibr" rid="R35">Stefan et al., 2020</xref>). Further, recent studies have indicated the roles of nasal bacteria in innate antiviral resistance to influenza virus infection or severity of the diseases (<xref ref-type="bibr" rid="R17">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="R29">Pillai et al., 2016</xref>). However, it remains unclear whether nasal bacteria critically regulates the generation of influenza virus-specific adaptive immune responses after influenza virus infection. In this study, we demonstrated that depletion of commensal bacteria in upper respiratory tract by intranasal administration of antibiotics enhanced the virus-specific antibodies response following influenza virus infection. Surprisingly, depletion of nasal bacteria by intranasal administration of antibiotics before influenza virus infection significantly reduced the virus titer at 2 days post infection. This is consistent with a previous report showing that antibiotic treatment significantly reduce influenza virus replication at 6 hours post infection (<xref ref-type="bibr" rid="R9">Gopinath et al., 2018</xref>). Intranasal application of antibiotics suppressed influenza virus replication through at least two possible mechanisms. First, intranasal administration of antibiotics enhances host resistance to influenza virus infection in a microbiota-independent manner (<xref ref-type="bibr" rid="R9">Gopinath et al., 2018</xref>). Second, disruption of nasal bacteria by intranasal antibiotic treatment may release PAMPs from the antibiotic-killed bacteria, which stimulate innate antiviral immune responses to suppress influenza virus replication (<xref ref-type="bibr" rid="R19">Matsuo et al., 2000</xref>). After 3 and 5 days post infection, the viral replication in upper respiratory tract became comparable between antibiotic-treated and control groups, indicating that the levels of influenza virus replication in upper respiratory tract is unlikely to account for increased levels of the virus-specific antibodies response in antibiotic-treated mice.</p>
<p id="P13">Since the primary targets of influenza virus are the nasal epithelial cells in upper respiratory tract, it is beneficial to induce the virus-specific nasal IgA antibody at the nasal mucosal epithelium. However, intranasal vaccination with split-virus vaccine alone is often insufficient to elicit proper immune responses at the upper respiratory tract. Therefore, adjuvants are required for a given vaccine to induce the vaccine-specific nasal IgA response. In developing intranasal vaccines, cholera toxin(CT) and <italic>Escherichia coli</italic> heat-labile toxin (LT) have been used as adjuvant to enhance nasal immune response (<xref ref-type="bibr" rid="R38">S. I. Tamura &amp; Kurata, 2000</xref>). Although CT and LT are effective adjuvants to enhance mucosal immune responses including secretory IgA responses, they have some side effects in humans, including Bell's palsy and nasal discharge (<xref ref-type="bibr" rid="R25">Mutsch et al., 2004</xref>). Therefore, several adjuvants that are as effective as CT or LT and are also safe for human use have been developed for clinical application with intranasal influenza vaccine (<xref ref-type="bibr" rid="R2">Ainai et al., 2010</xref>; <xref ref-type="bibr" rid="R5">Bracci et al., 2005</xref>; <xref ref-type="bibr" rid="R11">Ichinohe et al., 2005</xref>; <xref ref-type="bibr" rid="R31">Sjolander et al., 2001</xref>; <xref ref-type="bibr" rid="R32">Skountzou et al., 2010</xref>; <xref ref-type="bibr" rid="R33">Spinner et al., 2015</xref>). In this study, we show that intranasal vaccination with influenza virus HA vaccine and culturable oral bacteria from a healthy human volunteer induced significant levels of the vaccine-specific nasal IgA and serum IgG responses in a dose-dependent manner. All commensal bacterial strains tested, including <italic>S. salivarius</italic>, <italic>S. parasanguinis</italic>, or <italic>S. infantis</italic>, induced comparable levels of the HA-specific nasal IgA and serum IgG responses, suggesting that adjuvant activity of the oral bacteria is unlikely to account for strain specific. In addition to culturable oral bacteria from a healthy human volunteer, we demonstrated that disruption of nasal bacteria by lysozyme induced significant levels of the vaccine-specific antibodies response. Although relative amounts of nasal bacteria were significantly lower than that in the oral cavity, disruption of nasal bacteria by lysozyme could rescue the inability of nasal bacteria to generate the vaccine-specific antibodies response. In mice, nasal commensal microbiota are predominantly composed of gram-positive bacteria including <italic>Lactobacillus spp</italic>., <italic>Bacillus spp</italic>., <italic>Staphylococcus spp</italic>., and <italic>Streptococcus spp</italic>. (<xref ref-type="bibr" rid="R11">Ichinohe et al., 2011</xref>). In addition, <italic>Lactobacillus spp</italic>. were found to contain higher amounts of double-stranded RNA than the pathogenic bacteria (<xref ref-type="bibr" rid="R16">Kawashima et al., 2013</xref>). Since activation of TLRs by different PAMPs such as poly(I:C) and zymosan synergistically enhanced the nasal IgA response to intranasally administered influenza virus HA vaccine (<xref ref-type="bibr" rid="R2">Ainai et al., 2010</xref>), disruption of nasal bacteria could stimulate different TLRs to enhance the vaccine-specific antibodies response. Most TLRs signal though the adaptor protein MyD88 (<xref ref-type="bibr" rid="R15">Kawai &amp; Akira, 2010</xref>; <xref ref-type="bibr" rid="R21">Medzhitov, 2001</xref>). Although nasal epithelial cells express various TLRs (<xref ref-type="bibr" rid="R39">Tengroth et al., 2014</xref>; <xref ref-type="bibr" rid="R40">van Tongeren et al., 2015</xref>), deficiency of MyD88 in stromal compartment did not significantly affect the levels of nasal IgA and serum IgG responses following intranasal vaccination with influenza virus HA and culturable oral bacteria. Instead,MyD88-dependent signaling in the hematopoietic cells were required for adjuvant activity of intranasally administered oral bacteria. These data are consistent with previous studies showing that both TLR-induced dendritic cell maturation and B-cell activation are required for optimal antibody responses to T-dependent antigens (<xref ref-type="bibr" rid="R13">Iwasaki &amp; Medzhitov, 2015</xref>; <xref ref-type="bibr" rid="R28">Pasare &amp; Medzhitov, 2005</xref>).</p>
<p id="P14">In summary, our study demonstrated the effects of commensal microbiota in upper respiratory tract in the induction of the virus-specific adaptive immune responses after influenza virus infection or intranasal vaccination. Our data indicated that disruption of nasal bacteria by lysozyme or supplementation of oral bacteria from a healthy volunteer enhanced nasal IgA and serum IgG antibodies response to intranasally administered influenza virus HA or SARS-CoV-2 S proteins. Although the vaccinated animals significantly reduced the virus titer compared to unadjuvanted group or naÃ¯ve animals following high-dose of influenza virus or SARS-CoV-2 challenge, further studies are needed to establish the safety and efficacy of this vaccination method in an additional animal model such as nonhuman primate.</p>
</sec>
<sec id="S9" sec-type="materials | methods">
<title>Materials and methods</title>
<sec id="S10">
<title>Mice</title>
<p id="P15">Age- and sex-matched Balb/c mice obtained from Japan SLC, Inc. were used as WT controls. MyD88-deficient Balb/c mice were a gift from T. Taniguchi. All animal experiments were performed in accordance with the University of Tokyo's Regulations for Animal Care and Use, which were approved by the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo (approval number PA17â 69).</p>
</sec>
<sec id="S11">
<title>Cells</title>
<p id="P16">Madin-Darby canine kidney (MDCK) cells were grown in Eagle's minimal essential medium (E-MEM; Nacalai Tesque) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 Î¼g/ml). VeroE6 cells stably expressing transmembrane protease serine 2 (VeroE6/TMPRSS2; JCRB Cell Bank 1819) were maintained in Dulbecco's modified Eagle's medium (DMEM) low glucose (Cat#08456-65; Nacalai Tesque) supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 Î¼g/ml), and G418 (1mg/ml) (<xref ref-type="bibr" rid="R20">Matsuyama et al., 2020</xref>).</p>
</sec>
<sec id="S12">
<title>Depletion of nasal bacteria <italic>in vivo</italic>
</title>
<p id="P17">The antibiotic cocktail consisted of ampicillin sodium salt (1 g/L), neomycin sulfate (1 g/L), metronidazole (1 g/L), vancomycin hydrochloride (0.5 g/L), gentamicin (10 mg/L), penicillin (100 U/ml), streptomycin (100 U/ml), and amphotericin B (0.25 mg/L) (<xref ref-type="bibr" rid="R22">Moriyama &amp; Ichinohe, 2019</xref>). For intranasal treatment, mice were anaesthetized and 5 Î¼l of antibiotic was administered dropwise into each nostril using a pipette tip. All antibiotics with the exception of vancomycin hydrochloride were obtained from Nacalai Tesque. Vancomycin hydrochloride was obtained from Duchefa Biochemie.</p>
</sec>
<sec id="S13">
<title>Virus infection</title>
<p id="P18">WT A/Puerto Rico/8/34 (A/PR8) and A/Narita/1/09 (pdm09) influenza viruses were grown in allantoic cavities of 10-d-old fertile chicken egg at 35ËC for 2 d (<xref ref-type="bibr" rid="R24">Moriyama et al., 2020</xref>). Viral titer was quantified by a standard plaque assay using MDCK cells and viral stock was stored at â80ËC (<xref ref-type="bibr" rid="R23">Moriyama, Koshiba, &amp; Ichinohe, 2019</xref>). For intranasal infection, mice were fully anesthetized by i.p. injection of pentobarbital sodium (Somnopentyl, Kyoritsu Seiyaku Co., Ltd., Tokyo, Japan) and then infected by intranasal application of 30 Î¼l of virus suspension (1,000 pfu of A/PR8 or pdm09 in PBS). This procedure leads to upper and lower respiratory tract infection (<xref ref-type="bibr" rid="R22">Moriyama &amp; Ichinohe, 2019</xref>).</p>
<p id="P19">SARS-CoV-2 (a gift from Y. Kawaoka) was amplified on VeroE6/TMPRSS2 cells and stored at â80ËC until use. The infectious titer was determined by a standard plaque assay using VeroE6/TMPRSS2 cells, as described previously (<xref ref-type="bibr" rid="R12">Imai et al., 2020</xref>). For intranasal infection, one-month-old female Syrian hamsters (Japan SLC Inc.) were fully anesthetized by i.p. injection of pentobarbital sodium (Somnopentyl, Kyoritsu Seiyaku Co., Ltd., Tokyo, Japan) and then infected intranasally with 2Ã10<sup>6</sup> pfu (in 100 Î¼L) of SARS-CoV-2. All experiments with SARS-CoV-2 were performed in enhanced biosafety level 3 (BSL-3) containment laboratories at the University of Tokyo, in accordance with the institutional biosafety operating procedures.</p>
</sec>
<sec id="S14">
<title>Vaccination</title>
<p id="P20">For intranasal infection, mice were fully anesthetized by i.p. injection of pentobarbital sodium (Somnopentyl, Kyoritsu Seiyaku Co., Ltd., Tokyo, Japan) and then infected intranasally by dropping 2 Î¼l of PBS containing 1,000 pfu of A/PR8 into the nostril. The quadrivalent inactivated influenza vaccine (split-product virus vaccines, hemagglutinin [HA] vaccine) prepared for the 2015â2016 season and including A/California/7/2009 (H1N1), A/Switzerland/9715293/2013 (H3N2), B/Phuket/3073/2013, and B/Texas/2/2013 were purchased from Kaketsuken (Kumamoto, Japan). Mice were immunized by intranasal administration of the quadrivalent HA vaccine containing 150 ng of each HA with or without 5 Î¼g of lipopolysaccharide (LPS; InvivoGen), 5 Î¼g of poly(I:C) (InvivoGen), 250 Î¼g of lysozyme (Thermo Fisher Scientific), or 1 mg of culturable oral bacteria from a healthy volunteer.</p>
<p id="P21">SARS-CoV-2 spike S1+S2 ECD-His recombinant protein was purchased from Sino Biological Inc. (Cat# 40589-V08B1). Hamsters were immunized subcutaneously or intranasally with 1 Î¼g of the recombinant spike protein with or without 1 mg of culturable oral bacteria from a healthy volunteer.</p>
</sec>
<sec id="S15">
<title>Clinical specimens</title>
<p id="P22">Oral and nasal washes were collected from a healthy volunteer by rinsing the mouth with 50 ml of saline or washing the nasal cavity with 50 ml of saline using a syringe. The research protocol was approved by the Research Ethics Review Committee of the Institute of Medical Science, the University of Tokyo (approval number 2019-42-1121). For preparation of oral bacteria adjuvant, oral wash samples were grown in brain heart infusion broth (BD 237500) at 37ËC overnight, washed repeatedly, and resuspended in PBS (200 Î¼g/ml).</p>
</sec>
<sec id="S16">
<title>Bacterial recovery and identification</title>
<p id="P23">Oral and nasal washes were collected from a healthy volunteer as described above. Aliquots of 100Î¼l of serial 10-fold dilution of the oral and nasal wash were inoculated into brain heart infusion agar plates (BD 252109). After incubation at 37ËC overnight under the aerobic conditions, the bacterial colonies were grown in brain heart infusion broth (BD 237500) at 37ËC overnight. Bacterial DNA was isolated as described previously (<xref ref-type="bibr" rid="R22">Moriyama &amp; Ichinohe, 2019</xref>). A 300-bp portion of the 16S rRNA was amplified by PCR using specific primer pairs of 515F (5'-GTGCCAGCMGCCGCGGTAA-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3'), purified (Qiagen), sequenced, and the sequence compared by Blast analysis to known bacterial sequences.</p>
</sec>
<sec id="S17">
<title>Bone marrow chimera</title>
<p id="P24">Bone marrow chimeras were generated as described (<xref ref-type="bibr" rid="R27">Pang, Ichinohe, &amp; Iwasaki, 2013</xref>). WT and MyD88-deficient mice were Î³-irradiated with 6 Gy, then were reconstituted with 5 Ã 10<sup>6</sup> bone marrow cells of the appropriate genotype via i.v.injection and allowed to recover for 8 weeks before vaccination.</p>
</sec>
<sec id="S18">
<title>Measurement of virus titers</title>
<p id="P25">For measurement of influenza virus titer, bronchoalveolar (BAL) fluid was collected by washing the trachea and lungs of mice twice by injecting a total of 2 ml PBS containing 0.1% bovine serum albumin (BSA). The virus titer was measured as follows: aliquots of 200 Î¼l of serial 10-fold dilution of the BAL fluid by PBS containing 0.1% BSA were inoculated into MDCK cells in 6-well plates. After 1 hour of incubation, cells were washed with PBS thoroughly and overlaid with 2 ml of agar medium.</p>
<p id="P26">For measurement of SARS-CoV-2 titer, BAL fluid was collected by washing the trachea and lungs of hamsters twice by injecting a total of 2 ml DMEM containing 5% FBS. The virus titer was measured as follows: aliquots of 200 Î¼l of serial 10-fold dilution of the BAL fluid by DMEM containing 5% FBS were inoculated into VeroE6/TMPRSS2 cells in 6-well plates. After 1 hour of incubation, cells were washed with PBS thoroughly and overlaid with 2 ml of agar medium. The number of plaques in each well was counted 2 days after inoculation.</p>
</sec>
<sec id="S19">
<title>Enzyme-linked immunosorbent assay (ELISA)</title>
<p id="P27">Serum and nasal wash were collected from the immunized mice for measurement of the PR8- or HA-specific nasal IgA and serum IgG antibodies. Nasal wash was collected by washing the nasopharynx three times by injecting a total of 1 ml PBS containing 0.1% BSA. The levels of the PR8- or HA-specific nasal IgA and serum IgG antibodies were determined by ELISA as described previously (<xref ref-type="bibr" rid="R22">Moriyama &amp; Ichinohe, 2019</xref>). Standards for PR8- or HA-reactive IgA and IgG antibody titration were prepared from the nasal wash or serum of the virus-infected or vaccinated mice, and expressed as the same arbitrary units (160-unit). The antibody titers of unknown specimens were determined from the standard regression curve constructed by two fold serial dilution of the 160-unit standard for each assay.</p>
</sec>
<sec id="S20">
<title>Quantification and statistical analysis</title>
<p id="P28">Statistical significance was tested by one-way ANOVA followed by Tukey test or unpaired t tests with PRISM software (Version 5; GraphPad software). Data are presented as mean Â± SEM. Statistical details can be found directly in the figure legends. P values of less than 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Figures</label>
<media xlink:href="EMS109280-supplement-Supplementary_Figures.pdf" mimetype="application" mime-subtype="pdf" id="N66358" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S21">
<title>Acknowledgments</title>
<p>We thank Y. Kawaoka (University of Wisconsin and University of Tokyo) for providing SARS-CoV-2 and T. Taniguchi (The University of Tokyo) for MyD88-deficient mice. This work was supported by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (20H03491), the Research Program on Emerging and Re-emerging Infectious Diseases, of the Japan Agency for Medical Research and Development (AMED), the Yakult Bio-Science Foundation, the Hitachi Global Foundation, and the Mitsubishi foundation. M. M. is the Research Fellow of the Japan Society for the Promotion of Science.</p>
</ack>
<fn-group>
<fn id="FN2" fn-type="conflict">
<p id="P29">
<bold>Competing interests statement</bold>
</p>
<p id="P30">The authors declare no competing financial interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abt</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Monticelli</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Doering</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Alenghat</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sonnenberg</surname>
<given-names>GF</given-names>
</name>
<etal/>
<name>
<surname>Artis</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Commensal bacteria calibrate the activation threshold of innate antiviral immunity</article-title>
<source>Immunity</source>
<year>2012</year>
<volume>37</volume>
<issue>1</issue>
<fpage>158</fpage>
<lpage>170</lpage>
<comment>S1074-7613(12)00237-3 [pii]</comment>
<pub-id pub-id-type="doi">10.1016/j.immuni.2012.04.011</pub-id>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ainai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine</article-title>
<source>J Med Virol</source>
<year>2010</year>
<volume>82</volume>
<issue>3</issue>
<fpage>476</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1002/jmv.21694</pub-id>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asahi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<etal/>
<name>
<surname>Tamura</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines</article-title>
<source>J Immunol</source>
<year>2002</year>
<volume>168</volume>
<issue>6</issue>
<fpage>2930</fpage>
<lpage>2938</lpage>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassis</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Erb-Downward</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>VB</given-names>
</name>
<etal/>
<name>
<surname>Huffnagle</surname>
<given-names>GB</given-names>
</name>
</person-group>
<article-title>Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals</article-title>
<source>MBio</source>
<year>2015</year>
<volume>6</volume>
<issue>2</issue>
<fpage>e00037</fpage>
<pub-id pub-id-type="doi">10.1128/mBio.00037-15</pub-id>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bracci</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Canini</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Puzelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sestili</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Venditti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spada</surname>
<given-names>M</given-names>
</name>
<etal/>
<name>
<surname>Proietti</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level</article-title>
<source>Vaccine</source>
<year>2005</year>
<volume>23</volume>
<issue>23</issue>
<fpage>2994</fpage>
<lpage>3004</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.12.006</pub-id>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradley</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Finsterbusch</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schnepf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crotta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Llorian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>S</given-names>
</name>
<etal/>
<name>
<surname>Wack</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection</article-title>
<source>Cell Rep</source>
<year>2019</year>
<volume>28</volume>
<issue>1</issue>
<fpage>245</fpage>
<lpage>256 e244</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.105</pub-id>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Commensal bacteria in the upper respiratory tract regulate susceptibility to infection</article-title>
<source>Curr Opin Immunol</source>
<year>2020</year>
<volume>66</volume>
<fpage>42</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/j.coi.2020.03.010</pub-id>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W</given-names>
</name>
<etal/>
<name>
<surname>Shu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Human infection with a novel avian-origin influenza A (H7N9) virus</article-title>
<source>N Engl J Med</source>
<year>2013</year>
<volume>368</volume>
<issue>20</issue>
<fpage>1888</fpage>
<lpage>1897</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1304459</pub-id>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gopinath</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Rakib</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>van Zandt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>NA</given-names>
</name>
<etal/>
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner</article-title>
<source>Nat Microbiol</source>
<year>2018</year>
<volume>3</volume>
<issue>5</issue>
<fpage>611</fpage>
<lpage>621</lpage>
<pub-id pub-id-type="doi">10.1038/s41564-018-0138-2</pub-id>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Kumamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Peaper</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Microbiota regulates immune defense against respiratory tract influenza A virus infection</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2011</year>
<volume>108</volume>
<issue>13</issue>
<fpage>5354</fpage>
<lpage>5359</lpage>
<comment>1019378108 [pii]</comment>
<pub-id pub-id-type="doi">10.1073/pnas.1019378108</pub-id>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Moriyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>S</given-names>
</name>
<etal/>
<name>
<surname>Hasegawa</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection</article-title>
<source>J Virol</source>
<year>2005</year>
<volume>79</volume>
<issue>5</issue>
<fpage>2910</fpage>
<lpage>2919</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.79.5.2910-2919.2005</pub-id>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iwatsuki-Horimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hatta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Loeber</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Halfmann</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>N</given-names>
</name>
<etal/>
<name>
<surname>Kawaoka</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2020</year>
<volume>117</volume>
<issue>28</issue>
<fpage>16587</fpage>
<lpage>16595</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.2009799117</pub-id>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Control of adaptive immunity by the innate immune system</article-title>
<source>Nat Immunol</source>
<year>2015</year>
<volume>16</volume>
<issue>4</issue>
<fpage>343</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="doi">10.1038/ni.3123</pub-id>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jangra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De Vrieze</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rathnasinghe</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Laghlali</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Uvyn</surname>
<given-names>A</given-names>
</name>
<etal/>
<name>
<surname>Schotsaert</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.10.23.344085</pub-id>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>
<source>Nat Immunol</source>
<year>2010</year>
<volume>11</volume>
<issue>5</issue>
<fpage>373</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.1038/ni.1863</pub-id>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kosaka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Uchiyama</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>R</given-names>
</name>
<etal/>
<name>
<surname>Tsuji</surname>
<given-names>NM</given-names>
</name>
</person-group>
<article-title>Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-beta</article-title>
<source>Immunity</source>
<year>2013</year>
<volume>38</volume>
<issue>6</issue>
<fpage>1187</fpage>
<lpage>1197</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.024</pub-id>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>An</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>Nasal commensal Staphylococcus epidermidis enhances interferon-lambda-dependent immunity against influenza virus</article-title>
<source>Microbiome</source>
<year>2019</year>
<volume>7</volume>
<issue>1</issue>
<fpage>80</fpage>
<pub-id pub-id-type="doi">10.1186/s40168-019-0691-9</pub-id>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liew</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Appleyard</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brand</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Beale</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity</article-title>
<source>Eur J Immunol</source>
<year>1984</year>
<volume>14</volume>
<issue>4</issue>
<fpage>350</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1002/eji.1830140414</pub-id>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Asanuma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<etal/>
<name>
<surname>Tamura</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin)</article-title>
<source>Vaccine</source>
<year>2000</year>
<volume>18</volume>
<issue>24</issue>
<fpage>2713</fpage>
<lpage>2722</lpage>
<pub-id pub-id-type="doi">10.1016/s0264-410x(00)00055-4</pub-id>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shirato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>I</given-names>
</name>
<etal/>
<name>
<surname>Takeda</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2020</year>
<volume>117</volume>
<issue>13</issue>
<fpage>7001</fpage>
<lpage>7003</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medzhitov</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Toll-like receptors and innate immunity</article-title>
<source>Nat Rev Immunol</source>
<year>2001</year>
<volume>1</volume>
<issue>2</issue>
<fpage>135</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1038/35100529</pub-id>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>High ambient temperature dampens adaptive immune responses to influenza A virus infection</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2019</year>
<volume>116</volume>
<issue>8</issue>
<fpage>3118</fpage>
<lpage>3125</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1815029116</pub-id>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koshiba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral immune responses</article-title>
<source>Nat Commun</source>
<year>2019</year>
<volume>10</volume>
<issue>1</issue>
<fpage>4624</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-019-12632-5</pub-id>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maruzuru</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koshiba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Influenza Virus-Induced Oxidized DNA Activates Inflammasomes</article-title>
<source>iScience</source>
<year>2020</year>
<volume>23</volume>
<issue>7</issue>
<comment>101270</comment>
<pub-id pub-id-type="doi">10.1016/j.isci.2020.101270</pub-id>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mutsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bopp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Linder</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Steffen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland</article-title>
<source>N Engl J Med</source>
<year>2004</year>
<volume>350</volume>
<issue>9</issue>
<fpage>896</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawaoka</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Emergence and pandemic potential of swine-origin H1N1 influenza virus</article-title>
<source>Nature</source>
<year>2009</year>
<volume>459</volume>
<issue>7249</issue>
<fpage>931</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1038/nature08157</pub-id>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pang</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus</article-title>
<source>Nat Immunol</source>
<year>2013</year>
<volume>14</volume>
<issue>3</issue>
<fpage>246</fpage>
<lpage>253</lpage>
<comment>ni.2514 [pii]</comment>
<pub-id pub-id-type="doi">10.1038/ni.2514</pub-id>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasare</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Control of B-cell responses by Toll-like receptors</article-title>
<source>Nature</source>
<year>2005</year>
<volume>438</volume>
<issue>7066</issue>
<fpage>364</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="doi">10.1038/nature04267</pub-id>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillai</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Molony</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Martinod</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Tal</surname>
<given-names>MC</given-names>
</name>
<etal/>
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease</article-title>
<source>Science</source>
<year>2016</year>
<volume>352</volume>
<issue>6284</issue>
<fpage>463</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1126/science.aaf3926</pub-id>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosshart</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Vassallo</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Angeletti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hutchinson</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K</given-names>
</name>
<etal/>
<name>
<surname>Rehermann</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance</article-title>
<source>Cell</source>
<year>2017</year>
<volume>171</volume>
<issue>5</issue>
<fpage>1015</fpage>
<lpage>1028 e1013</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.09.016</pub-id>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sjolander</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Drane</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beezum</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pearse</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses</article-title>
<source>Vaccine</source>
<year>2001</year>
<volume>19</volume>
<issue>28-29</issue>
<fpage>4072</fpage>
<lpage>4080</lpage>
<pub-id pub-id-type="doi">10.1016/s0264-410x(01)00110-4</pub-id>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skountzou</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Martin Mdel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Koutsonanos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weldon</surname>
<given-names>W</given-names>
</name>
<etal/>
<name>
<surname>Compans</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine</article-title>
<source>Vaccine</source>
<year>2010</year>
<volume>28</volume>
<issue>24</issue>
<fpage>4103</fpage>
<lpage>4112</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.058</pub-id>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinner</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Oberoi</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Yorgensen</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Burkhart</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Plante</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually</article-title>
<source>Vaccine</source>
<year>2015</year>
<volume>33</volume>
<issue>43</issue>
<fpage>5845</fpage>
<lpage>5853</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.086</pub-id>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steed</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Christophi</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Kaiko</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>U</given-names>
</name>
<etal/>
<name>
<surname>Stappenbeck</surname>
<given-names>TS</given-names>
</name>
</person-group>
<article-title>The microbial metabolite desaminotyrosine protects from influenza through type I interferon</article-title>
<source>Science</source>
<year>2017</year>
<volume>357</volume>
<issue>6350</issue>
<fpage>498</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1126/science.aam5336</pub-id>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefan</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Commensal Microbiota Modulation of Natural Resistance to Virus Infection</article-title>
<source>Cell</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.10.047</pub-id>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ainai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Multihartina</surname>
<given-names>P</given-names>
</name>
<etal/>
<name>
<surname>Hasegawa</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2015</year>
<volume>112</volume>
<issue>25</issue>
<fpage>7809</fpage>
<lpage>7814</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1503885112</pub-id>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurata</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Defense mechanisms against influenza virus infection in the respiratory tract mucosa</article-title>
<source>Jpn J Infect Dis</source>
<year>2004</year>
<volume>57</volume>
<issue>6</issue>
<fpage>236</fpage>
<lpage>247</lpage>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamura</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Kurata</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine</article-title>
<source>Jpn J Infect Dis</source>
<year>2000</year>
<volume>53</volume>
<issue>3</issue>
<fpage>98</fpage>
<lpage>106</lpage>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tengroth</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Millrud</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Kvarnhammar</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kumlien Georen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Latif</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cardell</surname>
<given-names>LO</given-names>
</name>
</person-group>
<article-title>Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells</article-title>
<source>PLoS One</source>
<year>2014</year>
<volume>9</volume>
<issue>6</issue>
<fpage>e98239</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0098239</pub-id>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Tongeren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roschmann</surname>
<given-names>KIL</given-names>
</name>
<name>
<surname>Reinartz</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Luiten</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fokkens</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>de Jong</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>van Drunen</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Expression profiling and functional analysis of Toll-like receptors in primary healthy human nasal epithelial cells shows no correlation and a refractory LPS response</article-title>
<source>Clin Transl Allergy</source>
<year>2015</year>
<volume>5</volume>
<fpage>42</fpage>
<pub-id pub-id-type="doi">10.1186/s13601-015-0086-3</pub-id>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kadowaki</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Komase</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aizawa</surname>
<given-names>C</given-names>
</name>
<etal/>
<name>
<surname>Tamura</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K)</article-title>
<source>Vaccine</source>
<year>2002</year>
<volume>20</volume>
<issue>29-30</issue>
<fpage>3443</fpage>
<lpage>3455</lpage>
<pub-id pub-id-type="doi">10.1016/s0264-410x(02)00351-1</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Disruption of nasal bacteria enhances the virus-specific antibody responses following influenza virus infection.</title>
<p>(<bold>A and B</bold>) Mice were inoculated intranasally with an antibiotic cocktail (Abx) for 5 consecutive days. Two days later, mice were intranasally infected with 1,000 pfu of A/PR8 virus. The nasal wash and serum were collected at 4 weeks p.i., and the virus-specific nasal IgA and serum IgG titers were determined by ELISA. Open circles indicate values for individual mice. The data are from three independent experiments (mean Â± SEM). *<italic>P</italic> &lt; 0.05 and ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Disruption of nasal bacteria induces the HA-specific antibody responses after intranasal vaccination.</title>
<p>(<bold>A and B</bold>) Mice were immunized intranasally with quadrivalent HA vaccine with or without poly(I:C) or lysozyme twice in a 3-week interval. Two weeks later, the nasal wash and serum were collected and the HA-specific nasal IgA and serum IgG titers were determined by ELISA. Open circles indicate values for individual mice. The data are from three independent experiments (mean Â± SEM). **<italic>P</italic> &lt; 0.01 and ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Oral bacteria acts as adjuvant for intranasal vaccine.</title>
<p>(<bold>A and B</bold>) Mice were immunized intranasally with quadrivalent HA vaccine with or without LPS, poly(I:C), or culturable oral bacteria from mice or a healthy volunteer twice in a 3-week interval. Two weeks later, the nasal wash and serum were collected and the HA-specific nasal IgA and serum IgG titers were determined by ELISA. (<bold>C and D</bold>) Mice were immunized intranasally with quadrivalent HA vaccine with or without indicated amounts of oral bacteria from a healthy volunteer twice in a 3-week interval. Two weeks later, the nasal wash and serum were collected and the HA-specific nasal IgA and serum IgG titers were determined by ELISA. Open circles indicate values for individual mice. The data are from two independent experiments (mean Â± SEM). *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 and ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Adjuvant activity of <italic>S. salivarius, S. parasanguinis</italic>, and <italic>S. infantis</italic> for intranasal vaccine.</title>
<p>(<bold>A and B</bold>) Mice were immunized intranasally with quadrivalent HA vaccine with or without <italic>S. salivarius, S. parasanguinis</italic>, or <italic>S. infantis</italic> twice in a 3-week interval. Two weeks later, the nasal wash and serum were collected and the HA-specific nasal IgA and serum IgG titers were determined by ELISA. Open circles indicate values for individual mice. The data are from two independent experiments (mean Â± SEM). *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 and ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>Oral bacteria acts as adjuvant for intranasal vaccine.</title>
<p>(<bold>A-D</bold>) WT and MyD88-deficient mice were immunized intranasally with quadrivalent HA vaccine with or without culturable oral bacteria from a healthy volunteer (<bold>A and B</bold>) or lysozyme (<bold>C and D</bold>) twice in a 3-week interval. Two weeks later, the nasal wash and serum were collected and the HA-specific nasal IgA and serum IgG titers were determined by ELISA. Open circles indicate values for individual mice. The data are from two independent experiments (mean Â± SEM). ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f005"/>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<title>Oral bacteria acts as adjuvant for intranasal vaccine.</title>
<p>(<bold>A and B</bold>) WTâMyD88 KO and MyD88 KOâWT BM chimeric mice were immunized intranasally with quadrivalent HA vaccine with or without culturable oral bacteria from a healthy volunteer twice in a 3-week interval. Two weeks later, the nasal wash and serum were collected and the HA-specific nasal IgA and serum IgG titers were determined by ELISA. Open circles indicate values for individual mice. The data are from two independent experiments (mean Â± SEM). ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f006"/>
</fig>
<fig id="F7" position="float">
<label>Figure 7</label>
<caption>
<title>Protective effects of oral bacteria-adjuvanted intranasal vaccine against influenza virus infection.</title>
<p>Mice were immunized intranasally with quadrivalent HA vaccine with or without culturable oral bacteria from a healthy volunteer or lysozyme twice in a 3-week interval. Two weeks after the last vaccination, mice were challenged with 1,000 pfu of A/PR8 virus. The nasal wash of influenza virus-infected mice was collected at 3 days post infection, and viral titers were determined by plaque assay. Open circles indicate values for individual mice. The dashed line indicates the limit of virus detection. The data are from two independent experiments (mean Â± SEM). ***<italic>P</italic> &lt; 0.001; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f007"/>
</fig>
<fig id="F8" position="float">
<label>Figure 8</label>
<caption>
<title>Protective effects of oral bacteria-adjuvanted intranasal vaccine against SARS-CoV-2 infection.</title>
<p>(<bold>A-C</bold>) Hamsters were immunized subcutaneously or intranasally with the spike protein of SARS-CoV-2 with or without culturable oral bacteria from a healthy volunteer twice in a 3-week interval. Two weeks after the last vaccination, hamsters were challenged with 2Ã10<sup>6</sup> pfu of SARS-CoV-2. (<bold>A and B</bold>) Serum were collected at 3 days post infection. The spike protein- (<bold>A</bold>) or SARS-CoV-2- (<bold>B</bold>) specific serum IgG antibody titers were determined by ELISA. (<bold>C</bold>) The lung wash of SARS-CoV-2-infected hamsters was collected at 3 days post infection, and viral titers were determined by plaque assay. Open circles indicate values for individual hamsters. The data are from two independent experiments (mean Â± SEM). *<italic>P</italic> &lt; 0.05 and **<italic>P</italic> &lt; 0.01; (one-way ANOVA and Tukey's test).</p>
</caption>
<graphic xlink:href="EMS109280-f008"/>
</fig>
</floats-group>
</article>
